MYND ANALYTICS, INC. (OTCMKTS:MYAN) Files An 8-K Regulation FD Disclosure

MYND ANALYTICS, INC. (OTCMKTS:MYAN) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

MYnd Analytics, Inc. (the “Company”) has updated its investor presentation (the “Presentation”), which its senior management intends to use from time to time when interacting with investors and analysts, among others. The Company has posted the Presentation to its website. The Presentation may be accessed by going to the Company’s investor relations website at and clicking on “Investor Presentation”. The Presentation is also attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this report is being furnished, not filed, to Regulation FD. Accordingly, the information in Items 7.01 and 9.01 of this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.

Item 9.01 Financial Statements and Exhibits.

99.1 Investor Presentation

MYnd Analytics, Inc. Exhibit
EX-99.1 2 s108654_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1   GREATER ACCESS TO MORE EFFECTIVE TREATMENTS REDUCES TOTAL COST OF CARE January 2018 Investor Presentation NASDAQ: MYND   Investor Presentation DISCLAIMER This presentation contains “forward – looking statements” pursuant to the safe – harbor provisions of the Private Securities Litigation Reform Act of 1995 that include information relating to future events,…
To view the full exhibit click here


MYnd Analytics, Inc., formerly CNS Response, Inc., is a cloud-based predictive analytics company that provides objective clinical decision support to mental healthcare providers for the treatment of behavioral disorders, including depression, anxiety, bipolar disorder and post-traumatic stress disorder (PTSD). It uses its neurometric platform, PEER Online, to generate Psychiatric Electroencephalogram, Evaluation Registry Reports to predict the likelihood of response by an individual to certain medications for the treatment of behavioral disorders. The Company’s technology helps in evaluating pharmacotherapy options in patients suffering from non-psychotic behavioral disorders. PEER provides medical professionals with medication sensitivity data for a subject patient based upon the identification and correlation of treatment outcome information from other patients with similar neurophysiologic characteristics. This treatment outcome information is contained in the PEER Online database.

An ad to help with our costs